TuHURA Biosciences
HURA
8 hedge funds and large institutions have $338K invested in TuHURA Biosciences in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
100% more funds holding
Funds holding: 4 → 8 (+4)
2.75% more ownership
Funds ownership: 10.35% → 13.1% (+2.8%)
48% less capital invested
Capital invested by funds: $650K → $338K (-$312K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$169K |
| 2 |
Barclays
London,
United Kingdom
|
+$55K |
| 3 |
VF
Virtu Financial
New York
|
+$41K |
| 4 |
FIA
FNY Investment Advisers
New York
|
+$29.1K |
| 5 |
RE
RBC Europe
London,
United Kingdom
|
+$18.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$104K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$18K |
HURA Hedge Fund Activity: Q4 2019 in Review
8 of the 5,093 institutional investors tracked by Wall St. Rank reported a position in TuHURA Biosciences (HURA) for Q4 2019, worth a combined $338K — down 48% from $650K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new HURA positions and 2 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, adding an estimated $169K. The largest seller was CVI Holdings, exiting entirely with an estimated $104K sold.
- 8 institutional investors held TuHURA Biosciences (HURA) as of Q4 2019, up from 4 in Q3 2019.
- Funds reported $338K of TuHURA Biosciences stock for Q4 2019, down 48% quarter-over-quarter.
- 6 funds opened new TuHURA Biosciences positions in Q4 2019 and 2 closed out, a net change of +4 holders.
- The largest TuHURA Biosciences buyer in Q4 2019 was Sabby Management, an estimated $169K added.
- The largest TuHURA Biosciences seller in Q4 2019 was CVI Holdings, an estimated $104K sold.
Based on aggregated 13F filings for Q4 2019.